School of Breast Oncology Offers Intensive Retreat

Publication
Article
Oncology Live®October 2011
Volume 12
Issue 10

Joyce A. O'Shaughnessy explores the 8th Annual School of Breast Oncology, an interactive program designed to immerse oncology professionals in the latest science.

Joyce A. O'Shaughnessy

Joyce A. O'Shaughnessy, MD

Co-Director, Breast Cancer Research

Baylor Charles A. Sammons

Cancer Center

Texas Oncology/US Oncology

Dallas, TX

Joyce A. O'Shaughnessy, MD, an internationally known researcher in breast cancer, recently led the 8th Annual School of Breast Oncology, an interactive program designed to immerse oncology professionals in the latest science.

The program, offered through Physicians’ Education Resource, was scheduled for November 3-6, at the Emory Conference Center in Atlanta, Georgia.

“The School of Breast Oncology is a boot camp—a 4-day, intensive retreat to help oncologists fully understand state-of-the-art breast cancer treatment,” said O’Shaughnessy, co-director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center in Dallas, Texas.

“The meeting provides practical presentations based on day-to-day, best standards of care in significant detail and depth,” she said. “Plus, every evening there are lengthy multihour case discussions that work through the nuances in the areas of decision making for practitioners.”

The program provided a comprehensive review of the most recent data on aspects of breast cancer biology, diagnostics, prevention, and advances in treatment.

The evidence-based curriculum examined topics such as breast carcinogenesis and the management of high-risk disease, adjuvant chemotherapy and endocrine therapy, imaging modalities and their use, the management of HER2-positive disease, treatment of metastatic disease, and survivorship.

“It’s a very intensive, hands-on meeting that ensures participants are fully up to speed in being able to diagnose, prevent, and treat breast cancer—whether you’re a medical oncologist, a surgeon, or a radiation oncologist,” O’Shaughnessy said. “For the hands-on practitioner who takes care of breast cancer patients, this is your course.”

For further information on PER conferences, visit www.cancerlearning.com.

Related Videos
Nan Chen, MD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Ko Un “Clara” Park, MD
Erin Frances Cobain, MD
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Carlos Arteaga, MD
Video 2 - "NCCN Guidelines vs Real-World Practice: Risk Stratifying HR+/HER2- Early Breast Cancer"
Reshma L. Mahtani, DO